- Home
- SNY vs GILD Comparison
SNY vs GILD Comparison
Compare SNY & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNY
- GILD
- Stock Information
- Founded
- SNY 1994
- GILD 1987
- Country
- SNY France
- GILD United States
- Employees
- SNY N/A
- GILD N/A
- Industry
- SNY Biotechnology: Pharmaceutical Preparations
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SNY Health Care
- GILD Health Care
- Exchange
- SNY Nasdaq
- GILD Nasdaq
- Market Cap
- SNY 123.6B
- GILD 129.9B
- IPO Year
- SNY N/A
- GILD 1992
- Fundamental
- Price
- SNY $52.13
- GILD $98.16
- Analyst Decision
- SNY Buy
- GILD Buy
- Analyst Count
- SNY 2
- GILD 26
- Target Price
- SNY $62.50
- GILD $108.00
- AVG Volume (30 Days)
- SNY 3.1M
- GILD 8.7M
- Earning Date
- SNY 04-24-2025
- GILD 04-24-2025
- Dividend Yield
- SNY 3.09%
- GILD 3.22%
- EPS Growth
- SNY 39.56
- GILD 1118.07
- EPS
- SNY 5.45
- GILD 4.73
- Revenue
- SNY $48,817,552,946.00
- GILD $28,735,000,000.00
- Revenue This Year
- SNY $5.35
- GILD $1.88
- Revenue Next Year
- SNY $6.69
- GILD $3.95
- P/E Ratio
- SNY $9.56
- GILD $20.75
- Revenue Growth
- SNY N/A
- GILD 4.68
- 52 Week Low
- SNY $45.80
- GILD $62.07
- 52 Week High
- SNY $60.12
- GILD $119.96
- Technical
- Relative Strength Index (RSI)
- SNY 44.93
- GILD 36.39
- Support Level
- SNY $51.67
- GILD $93.37
- Resistance Level
- SNY $55.73
- GILD $107.17
- Average True Range (ATR)
- SNY 0.90
- GILD 3.64
- MACD
- SNY 0.10
- GILD -0.64
- Stochastic Oscillator
- SNY 31.69
- GILD 33.76
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).